Special Courses pdf
CODE: SPSC20
Controversy Session: Stereotactic Radiation for Oligo-Metastasis: New Paradigm or Wishful Thinking?
  • DATE:Monday
  • TIME:07:15-08:15 AM
  • LOCATION: E350
PARTICIPANTS
  • Ralph Weichselbaum MD - Stockholder, Catherex, IncStockholder, RadiogeneticsStockholder, Midway Pharmaceuticals, IncStockholder, Bristol-Myers Squibb CompanyStockholder, MagiStockholder, RefleXion Medical IncStockholder, AstraZeneca PLCStockholder, OncosenescenceResearch Consultant, Catherex, IncResearch Consultant, RadiogeneticsResearch Consultant, Midway Pharmaceuticals, IncResearch Consultant, Bristol-Myers Squibb CompanyResearch Consultant, MagiResearch Consultant, RefleXion Medical IncResearch Consultant, AstraZeneca PLCResearch Consultant, Oncosenescence
  • Moderator
  • Simon Lo MD - Nothing to disclose.
  • Moderator
  • David Palma MD, FRCPC - Nothing to disclose.
  • Joseph Salama MD - Nothing to disclose.
CME CONTENT CODES
  •   Radiation Oncology
CREDIT CATEGORIES
  • AMA PRA Category 1 Credit™: 1.0
  • ARRT Category A+ Credit: 1.0
SUBSPECIALTY CONTENT
  • Radiation Oncology

LEARNING OBJECTIVES
The learner will be able to: 1) Identify the prognostic variability of those patients who present with or who develop metastatic cancer. 2) Critically analyze the use of Intensity Modulated Radiation Therapy (IMRT) and Stereotactic Body Radiation Therapy (SBRT) for subsets of patients with limited metastatic disease. 3) Compare indications and contraindications of higher technology radiotherapy procedures for patients with end-of-life cancer. 4) Demonstrate an understanding of the opposing forces of increasing needs and resource limitations on the practice of palliative radiotherapy.


No published email address listed.